Small-molecule inhibitors of EGFR, such as gefitinib and erlotinib, have shown antitumor activity and have alleviated symptoms in NSCLC patients who were previously treated with standard chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.